stella
beta
Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals — Stella
Recruiting
Back to HIV Infected Individuals trials
Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations
(3 sites)
Israel
Rambam Medical Center, Haifa
Hadassah Hebrew University Medical Center, Jerusalem
Sheba Medical Center, Ramat Gan
View full record on ClinicalTrials.gov